States' Medical Marijuana Patient Protection Act

referredUnited States· United States Congress· EN

Introduced

14 February 2013

Last action

8 April 2013 · Referred

Status

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, And Investigations.

Summary

States' Medical Marijuana Patient Protection Act - Requires the Secretary of Health and Human Services (HHS), within six months of enactment of this Act, to submit to the Administrator of the Drug Enforcement Administration (DEA) a recommendation on the listing of marijuana within the Controlled Substances Act (CSA) and to recommend listing it as other than a Schedule I or Schedule II substance. Requires the Administrator of DEA, within one year of enactment of this Act, based upon such recommendation, to issue a notice of proposed rulemaking for the rescheduling of marijuana within the CSA, which shall include a recommendation to list marijuana as other than a Schedule I or Schedule II substance. Declares that no provision of the CSA or the Federal Food, Drug and Cosmetic Act shall, in a state in which the medical use of marijuana is legal under state law, prohibit or otherwise restrict: (1) the prescription or recommendation of marijuana for medical use by a medical professional or the certification by a medical professional that a patient has a condition for which marijuana may have therapeutic benefit; (2) an individual from obtaining, manufacturing, possessing, or transporting within his or her state marijuana for medical purposes, provided the activities are authorized under state law; (3) a pharmacy or other entity authorized to distribute medical marijuana from obtaining, possessing, or distributing marijuana to authorized individuals; or (4) an entity authorized by a state or local government from producing, processing, or distributing marijuana for such purposes. Requires the Attorney General to delegate responsibility for control over access to marijuana for research into its potential therapeutic and medicinal uses to an entity of executive branch that is not focused on researching the addictive properties of substances. Requires such entity to take appropriate actions to ensure that an adequate supply of marijuana is available for therapeutic and medicinal research.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

14 February 2013
Introduced
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
14 February 2013
Introduced
Sponsor introductory remarks on measure. (CR E150)
Source: IntroReferral
14 February 2013
Introduced
Introduced in House
Source: IntroReferral
14 February 2013
Introduced
Introduced in House
Source: IntroReferral
15 February 2013
Referred
Referred to the Subcommittee on Health.
Source: Committee
8 April 2013
Referred
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, And Investigations.
Source: Committee

Votes

No vote records are attached yet.

Versions

Introduced in House · 14 February 2013 · Official file

Documents

3 official files

Introduced in House (text)

View file Download file

Introduced in House (text)
Introduced in House · EN · 14 February 2013
View Download Open at official source
Introduced in House (PDF)
Introduced in House · EN · 14 February 2013
View Download Open at official source
Introduced in House
summary · EN · 14 February 2013
Open at official source

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/113th-congress/house-bill/689
Open data entity: https://api.congress.gov/v3/bill/113/hr/689
us · 113-hr-689 · source updated 12 August 2025